Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, TotalEnergies, Linde and AT&T

For immediate release

Chicago, IL – June 14, 2022 – announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Berkshire Hathaway Inc. (BRK.B), AbbVie Inc. ABBV, TotalEnergies SE TTE, Linde plc LIN and AT&T Inc. T.

Here are the highlights from Monday’s analyst blog:

Key analyst reports for Berkshire Hathaway, AbVie and TotalEnergies

Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc., AbbVie Inc. and TotalEnergies SE. These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.

You can see all research reports from today here >>>

Berkshire Hathaway shares have outperformed the Zacks Insurance – P&C industry over the past year (+1.1% vs. -3.3%). The company is one of the largest P&C insurance companies by premium volume. Berkshire’s inorganic growth story remains impressive with strategic acquisitions.

A strong cash position supports earnings accretive top-up buybacks and indicates the company’s financial flexibility. Continued growth in the insurance business is fueling free float growth, driving earnings and generating maximum return on equity.

The non-insurance business is performing better with increased revenues in recent years. A strong level of capital provides further momentum. However, exposure to catastrophe losses induces earnings volatility and also affects Berkshire’s P&C underwriting results. Huge capital expenditure remains a headwind for the business.

(You a read the full Berkshire Hathaway research report here >>>)

AbbVie shares have outperformed industry Zacks Large Cap Pharmaceuticals over the past year (+27.6% vs. +15.8%). The Zacks analyst believes the company has successfully expanded the labels of its cancer drugs, Imbruvica and Venclexta.

It has several new drugs in its pipeline, which have the potential to generate revenue once Humira loses US exclusivity in 2023. Skyrizi and Rinvoq are doing well, buoyed by new indication approvals. It has an impressive late-stage pipeline and several early/mid-stage candidates that have blockbuster potential.

The acquisition of Allergan has diversified AbbVie’s revenue base into new therapeutic areas, enhancing its long-term growth potential. However, there are concerns about long-term sales growth once Humira generics enter the US market. Growing competition from new therapies is hurting sales of Imbruvica. AbbVie shares have outperformed the industry this year so far.

(You a read the full research report on AbbVie here >>>)

TotalEnergies shares have gained +44.3% over the past year versus Zacks Oil and Gas – Refining and Marketing’s +19.0% gain. Zacks analyst believes the company is benefiting from new startups, rising commodity prices, well-spread LNG assets and an expanding upstream portfolio that is exposed to growing hydrocarbon-producing regions fast.

TTE is rationalizing its portfolio through acquisitions, partnerships and divestitures. TTE regularly invests to expand its renewable operations and aims to achieve net zero emissions by 2050.

TTE has sufficient cash to service its debts. However, TTE’s profitability is likely to have been affected by the natural decline of oil and natural gas deposits. TTE remains exposed to acquisition risks as these assets contribute a significant volume of production. TTE has operations in some politically troubled regions and the ongoing conflict between Russia and Ukraine could affect profitability.

(You a read the full research report on TotalEnergies here >>>)

Other noteworthy reports we are featuring today include Linde plc and AT&T Inc.

Why haven’t you watched Zacks best action?

Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.

See Free Stocks >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit for more information on the performance figures displayed in this press release.

How to take advantage of the hot electric vehicle industry

Global electric car sales in 2021 more than doubled from 2020. And today, electric vehicle (EV) technology and the very nature of the business is changing rapidly. The next push for future tech is happening now, and investors who get in early could see windfall profits.

See the best Zacks stocks to take advantage of the electric vehicle revolution >>

Click to get this free report

AT&T Inc. (T): Free Inventory Analysis Report

Berkshire Hathaway Inc. (BRK.B): Free Stock Analysis Report

AbbVie Inc. (ABBV): Free Stock Analysis Report

Linde plc (LIN): Free Stock Analysis Report

ADR (TTE) sponsored by TotalEnergies SE: free stock analysis report

To read this article on, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Source link